FHI Clinical, Inc announced its launch as a full-service contract research organization (CRO) with responsive approaches and proven solutions to manage complex clinical research in resource-limited settings around the world.
With a focus on mission-driven clinical research, FHI Clinical addresses unmet research needs across dozens of therapeutic areas, while supporting the development of life-saving vaccines and medicines. Whether working from a state-of-the-art facility or in a low-tech, rural setting, FHI Clinical provides services tailored to meet its clients’ diverse study needs, from protocol design and site assessment to trial planning, implementation and management.
FHI Clinical is led by Ted FitzGerald, who transitions from Director of Global Research Services (GRS), FHI 360 to President and CEO of the new company. In his more than a decade of work for FHI 360, FitzGerald led clinical research services, business development and administrative teams. The senior management team also includes:
The FHI Clinical Board of Directors is composed of:
FHI Clinical operates as an independent, commercial subsidiary of FHI 360, an international nonprofit working to improve the health and well-being of people in the United States and around the world. FHI Clinical is headquartered in downtown Durham, North Carolina.
“FHI 360’s global reach and reputation for excellence has enabled us to provide technical, regulatory and cultural expertise in regions where the needs for clinical research are greatest,” said Ted FitzGerald, FHI Clinical president and CEO. “As an independent subsidiary, FHI Clinical has the best of both worlds - access to FHI 360’s global platform and technical expertise, and the flexibility to implement systems and processes designed for both commercial and public sector clients.”
FHI Clinical joins FHI 360’sfamily of organizations, which includes two other recently launched subsidiaries.
“FHI Clinical will enable us to further expand our social impact,” said Patrick Fine, Chief Executive Officer of FHI 360. “Each member of the FHI 360 family operates differently, yet together we are guided by the same vision: to create a world in which all individuals and communities have the opportunity to reach their highest potential. I’m confident that FHI Clinical will deliver on that mission.”
For more information visit fhiclinical.com or contact us at info@fhiclinical.com or 919.321.3321
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.